Vinorelbine

Vinorelbine

SCHEMBL4765

CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8

The experimentally established mechanism targets of Vinorelbine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A known ✓ P04350 7/20 1.00
TUBB known ✓ P07437 7/20 1.00
TUBA3C known ✓ P0DPH7 7/20 1.00
TUBA1B known ✓ P68363 7/20 1.00
TUBA4A known ✓ P68366 7/20 1.00
TUBB4B known ✓ P68371 7/20 1.00
TUBB3 known ✓ Q13509 7/20 1.00
TUBB2A known ✓ Q13885 7/20 1.00
TUBB8 known ✓ Q3ZCM7 7/20 1.00
TUBA3E known ✓ Q6PEY2 7/20 1.00
TUBA1A known ✓ Q71U36 7/20 1.00
TUBA1C known ✓ Q9BQE3 7/20 1.00
TUBB6 known ✓ Q9BUF5 7/20 1.00
TUBB2B known ✓ Q9BVA1 7/20 1.00
TUBB1 known ✓ Q9H4B7 7/20 1.00
MEN1 O00255 5/20 1.00
KMT2A Q03164 5/20 1.00
CYP3A4 P08684 5/20 1.00
TACR2 P21452 1/20 1.00
OPRM1 P35372 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Vinorelbine SCHEMBL12277732 1.00 TUBB4A (1.00) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Vinorelbine SCHEMBL16786345 1.00 TUBB4A (1.00) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Vinorelbine SCHEMBL13575786 1.00 TUBB4A (1.00) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Vinorelbine SCHEMBL13524297 1.00 TUBB4A (1.00) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Vinorelbine SCHEMBL10018526 1.00 TUBB4A (1.00) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Vinorelbine SCHEMBL23077835 1.00 TUBB4A (1.00) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Vinorelbine SCHEMBL1653160 1.00 TUBB4A (1.00) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Vinorelbine SCHEMBL18220724 1.00 TUBB4A (1.00) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Vinorelbine SCHEMBL21610430 1.00 TUBB4A (1.00) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Vinorelbine SCHEMBL15113116 1.00 TUBB4A (1.00) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 154763 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144890-A1 ANTIBODY DRUG CONJUGATE COMPRISING NMT INHIBITOR CONJUGATED TO AN ANTIBODY MyricX Pharma Limited (GB) 2026-05-28 US claimed
EP-4748859-A2 CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF The Regents of the University of California (US) 2026-05-27 EP claimed
EP-4747263-A1 LIPID NANOPARTICLES AND USES THEREOF University of Connecticut (US) 2026-05-27 EP claimed
CN-122075497-A Use of NLRP3 agonist for tumor treatment 2026-05-26 CN claimed
US-12637498-B2 PDLIM2 as a biomarker for cancer and as an anti-cancer treatment target University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2026-05-26 US claimed
CN-116209439-B Cereblon protein modulators Saint Jude Children's Research Hospital Ltd. (US) 2026-05-26 CN claimed
US-20260137700-A1 PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE SK BIOPHARMACEUTICALS CO LTD (KR) 2026-05-21 US claimed
US-20260137686-A1 SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF IMPACT THERAPEUTICS SHANGHAI INC (CN) 2026-05-21 US claimed
US-20260141533-A1 QUANTITATIVE IMAGING BIOMARKER FOR LUNG CANCER THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2026-05-21 US claimed
WO-2026105121-A1 ANTICANCER FORMULATIONS AND USES THEREOF INTRAGEL THERAPEUTICS LTD. (IL) 2026-05-21 WO claimed
WO-1997040835-A1 TREATMENT OF CARCINOMAS USING SQUALAMINE IN COMBINATION WITH OTHER ANTI-CANCER AGENTS MAGAININ PHARMACEUTICALS INC. (US) 1997-11-06 WO claimed
EP-0804173-A1 CONTROLLED RELEASE BIODEGRADABLE MICROSPHERES AND METHOD OF PREPARATION PIERRE FABRE MEDICAMENT (FR) 1997-11-05 EP claimed
US-5620985-A ANTICANCER AGENTS PIERRE FABRE MEDICAMENT (FR) 1997-04-15 US claimed
EP-0709090-A2 Compositions for treating resistant tumors ELI LILLY AND COMPANY (US) 1996-05-01 EP claimed
WO-1996011677-A1 METHODS FOR TREATING RESISTANT TUMORS ELI LILLY AND COMPANY (US) 1996-04-25 WO claimed
WO-1995028149-A1 CONTROLLED RELEASE BIODEGRADABLE MICROSPHERES AND METHOD OF PREPARATION PIERRE FABRE MEDICAMENT (FR) 1995-10-26 WO claimed
EP-0393575-B1 Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent SEARLE & CO (US) 1994-03-16 EP claimed
EP-0393575-A1 Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent G.D. Searle & Co. (US) 1990-10-24 EP claimed
EP-0317401-A1 Pharmaceutical composition for parenteral administration of navelbine PIERRE FABRE MEDICAMENT (FR) 1989-05-24 EP claimed
US-4307100-A Nor bis-indole compounds usable as medicaments AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (ANVAR) (FR) 1981-12-22 US claimed